Dr. Petros Grivas is an oncologist with expertise in treating genitourinary cancers such as bladder cancer, prostate cancer and testicular cancer. His clinical research helped lead to FDA approval of new drugs to treat the most common type of bladder cancer. Dr. Grivas currently leads clinical trials that investigate the use of checkpoint inhibitors. These immunotherapy drugs release the brakes on a patient’s immune system and help it mount a better response to cancer.